Cart
sales@molnova.com
BRD-73954
CAS No. 1440209-96-0
BRD-73954( BRD73954 )
Catalog No. M11867 CAS No. 1440209-96-0
The first HDAC6/8 dual inhibitor with IC50s of 36/120 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 45 | In Stock |
|
| 5MG | 81 | In Stock |
|
| 10MG | 136 | In Stock |
|
| 25MG | 273 | In Stock |
|
| 50MG | 412 | In Stock |
|
| 100MG | 606 | In Stock |
|
| 500MG | 1287 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBRD-73954
-
NoteResearch use only, not for human use.
-
Brief DescriptionThe first HDAC6/8 dual inhibitor with IC50s of 36/120 nM.
-
DescriptionThe first HDAC6/8 dual inhibitor with IC50s of 36/120 nM; show no significant inhibition for other HDAC isoforms (IC50>9 uM); robustly increase in α-tubulin acetylation, has no change in the acetylation state of H3 in Hela cells.
-
In VitroBRD73954 (10 μM; 48 h; HeLa cells) inhibits HDAC6 activity via upregulation of Ac-Tubulin. Western Blot Analysis Cell Line:HeLa cells Concentration:10 μM Incubation Time:48 hours Result:Increased inα-tubulin acetylation, no change in the acetylation state of H3 was observed.
-
In Vivo——
-
SynonymsBRD73954
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC2|HDAC4|HDAC6|HDAC8
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1440209-96-0
-
Formula Weight284.3098
-
Molecular FormulaC16H16N2O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 35 mg/mL
-
SMILESC1=CC=C(C=C1)CCNC(=O)C2=CC(=CC=C2)C(=O)NO
-
Chemical Name1,3-Benzenedicarboxamide, N1-hydroxy-N3-(2-phenylethyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Olson DE, et al. J Med Chem. 2013 Jun 13;56(11):4816-20.
molnova catalog
related products
-
HDACi-4b
A benzamide-type HDAC inhibitor with IC50 of 78 uM for changes of FXN mRNA in affected GM15850 cells.
-
PCI-24781
A broad spectrum HDAC inhibitor; inhibits pure recombinant HDAC1 with Ki of 7 nM.
-
ACY-241
ACY-241, also known as Citarinostat, is a potent, selective and orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity.
